{"id":"NCT01446042","sponsor":"Acerus Pharmaceuticals Corporation","briefTitle":"Safety and Efficacy of Intranasal TBS-1 Treatment of Male Hypogonadism","officialTitle":"A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of Intranasal TBS-1 in the Treatment of Male Hypogonadism With Sequential Safety Extension Periods of 90 and 180 Days","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-09","primaryCompletion":"2012-12","completion":"2013-03","firstPosted":"2011-10-04","resultsPosted":"2018-06-13","lastUpdate":"2018-06-13"},"enrollment":306,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Male Hypogonadism"],"interventions":[{"type":"DRUG","name":"Testosterone","otherNames":[]},{"type":"DRUG","name":"Testosterone","otherNames":[]}],"arms":[{"label":"TBS-1 - b.i.d.","type":"EXPERIMENTAL"},{"label":"TBS-1 - t.i.d.","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine the efficacy (based on the pharmacokinetic profile of testosterone) and safety of TBS-1 in the treatment of hypogonadal men","primaryOutcome":{"measure":"Serum Testosterone Cavg","timeFrame":"90 days","effectByArm":[{"arm":"TBS-1 - b.i.d.","deltaMin":76,"sd":null},{"arm":"TBS-1 - b.i.d./t.i.d.","deltaMin":43,"sd":null},{"arm":"TBS-1 - t.i.d.","deltaMin":61,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":8,"exclusionCount":28},"locations":{"siteCount":30,"countries":["United States"]},"refs":{"pmids":["26695758"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":142},"commonTop":["Rhinorrhoea","Epistaxis","Parosmia","Nasopharyngitis","Nasal discomfort"]}}